by October Gallery
LONDON (Reuters) – Britain’s AstraZeneca Plc (AZN.L) has approached U.S. rival Gilead Sciences Inc (GILD.O) about a possible merger that would form one the world’s largest drug companies, Bloomberg News…
FILE PHOTO: Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau (Reuters) –…
(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to…
(Reuters) – An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc’s combination drug to reduce the risk of sexually acquired HIV infection in men and transgender…
LOS ANGELES (Reuters) – Gilead Sciences Inc (GILD.O) hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker…
(Reuters) – U.S. antiviral drugmaker Gilead Sciences (GILD.O) will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV (GLPG.AS), news that lifted Galapagos’s shares…
(Reuters) – Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG’s Daniel O’Day as its new chief executive, tapping an industry veteran to fill a management vacuum. FILE PHOTO:…
LONDON (Reuters) – A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify its use on Britain’s state-funded health service, the country’s healthcare…